Surbhi created a new blog entry
16 hours, 48 minutes ago public
X-Linked Hypophosphatemia XLH Treatment Market: How Is Burosumab Becoming the Fastest-Growing Targeted Therapy Replacing Conventional Management?
Burosumab for X-linked hypophosphatemia — the anti-FGF23 monoclonal antibody subcutaneous injection for phosphate-wasting rickets and osteomalacia representing the fastest-growing targeted...